SILVER-Seq™ (Small Input Liquid Volume Extracellular RNA Sequencing) efficiently sequences both integral and fragmented extracellular RNAs (exRNAs) from a small droplet (5–7 microliters) of liquid biopsy, including human serum, plasma, saliva, and aqueous humor. Users order by the number of liquid biopsy samples and Genemo will provide shipping instructions for users to ship the samples to Genemo. Genemo will carry out SILVER-Seq™ and provide the sequencing data to the users. Genemo will also provide to users processed SILVER-Seq™ data that include all the detected exRNAs including miRNAs, antisense RNAs, and exRNAs derived from lncRNAs and mRNAs and their expression levels (Tags Per Million, TPM).
We accept four types of samples: serum, plasma, saliva, and aqueous humor. Sample volume should be at least 7µL. We recommend 15µL or more. Samples should be kept in nuclease-free (PCR clean) tubes and stored at -70°C to -80°C.
Genemo will perform a 75-cycle single-end sequencing for the submitted sample. The minimal number of reads per sample is 3 million. The sequencing results, including FASTQ files, mapping results, QC reports, can be downloaded from our data server.
We are here to help you to develop your RNA biomarkers. Please inquire for co-development pricing.
BEING PATIENT – Researchers discovered a new biomarker associated with Alzheimer’s disease—high blood levels of RNA from a gene known as PHGDH.
SAN DIEGO – Researchers at the UCSD in collaboration with Genemo discovered that high blood levels of RNA produced by the PHGDH gene could serve as a biomarker for early detection of Alzheimer's disease.
NEW YORK – Genemo, a California startup, has launched an extracellular RNA sequencing service that it hopes to develop into companion diagnostics.